<DOC>
	<DOCNO>NCT02829034</DOCNO>
	<brief_summary>This study look see give ranolazine subject stable pulmonary hypertension therapy right ventricular dysfunction ( RVEF &lt; 45 % ) improve health improve right ventricular ( RV ) function .</brief_summary>
	<brief_title>Targeting Right Ventricle Pulmonary Hypertension Gilead</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Symptomatic pulmonary hypertension base one follow criterion : Idiopathic pulmonary arterial hypertension Familial pulmonary arterial hypertension Pulmonary hypertension associate connective tissue disease Chronic thromboembolic pulmonary hypertensionnonsurgical/distal vessel disease patient reluctant go surgery within 6month period willing participate Simple congenital repair atrial septal defect ventricular septal defect unrepaired small atrial septal defect ventricular septal defect persistent proportion pulmonary arterial hypertension Group 3 patient component pulmonary arterial hypertension *Pulmonary hypertension cause condition affect vein small vessel lung Sickle cell disease Group 5 pulmonary hypertension polycythemia vera Essential thrombocythemia Sarcoidosis Vasculitis Metabolic disorder World Health Organization functional class II , III , IV Mean pulmonary artery pressure &gt; 25 mmHg rest Pulmonary capillary wedge pressure leave ventricular end diastolic pressure &lt; 15 mmHg Pulmonary vascular resistance &gt; 3 mmHg/L/min Right ventricle ejection fraction &lt; 45 % 6minute walk test distance &gt; 50 meter Previous treatment prior sensitivity ranolazine Any family history correct QT interval prolongation , congenital long QT syndrome , receive drug prolong correct QT interval Parenchymal lung disease show total lung capacity &lt; 50 % predict OR force expiratory volume one second/forced vital capacity &lt; 50 % Portal hypertension associate chronic liver disease Left side heart disease include follow : moderate great aortic mitral valve disease , Any leave ventricle cardiomyopathy , Left ventricular systolic dysfunction define ejection fraction &lt; 50 % , Symptomatic coronary artery disease Uncontrolled systemic hypertension Implantable cardioverterdefibrillator , Pacemaker , hazardous metallic implant contraindication MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>right ventricular function</keyword>
	<keyword>ranolazine</keyword>
</DOC>